Literature DB >> 15956097

Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia.

Santiago Grau, José A Morales-Molina, Javier Mateu-de Antonio, Mónica Marín-Casino, Francisco Alvarez-Lerma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15956097     DOI： 10.1093/jac/dki202

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  9 in total

1.  Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.

Authors:  Chao Chen; Dai-Hong Guo; Xiutang Cao; Yun Cai; Yuanjie Xu; Man Zhu; Liang Ma
Journal:  Curr Ther Res Clin Exp       Date:  2012-12

2.  Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients.

Authors:  Julien Cazavet; Fanny Vardon Bounes; Stéphanie Ruiz; Thierry Seguin; Laure Crognier; Antoine Rouget; Olivier Fourcade; Vincent Minville; Jean-Marie Conil; Bernard Georges
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

3.  Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.

Authors:  H-Y Dong; J Xie; L-H Chen; T-T Wang; Y-R Zhao; Y-L Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-12       Impact factor: 3.267

4.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 5.  A Review of Population Pharmacokinetic Analyses of Linezolid.

Authors:  Enrique Bandín-Vilar; Laura García-Quintanilla; Ana Castro-Balado; Irene Zarra-Ferro; Miguel González-Barcia; Manuel Campos-Toimil; Víctor Mangas-Sanjuan; Cristina Mondelo-García; Anxo Fernández-Ferreiro
Journal:  Clin Pharmacokinet       Date:  2022-06-14       Impact factor: 5.577

6.  Clinical population pharmacokinetics and toxicodynamics of linezolid.

Authors:  Lauren M Boak; Craig R Rayner; M Lindsay Grayson; David L Paterson; Denis Spelman; Sharmila Khumra; Blair Capitano; Alan Forrest; Jian Li; Roger L Nation; Jurgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

7.  Risk factors for linezolid-associated thrombocytopenia in adult patients.

Authors:  B Natsumoto; K Yokota; F Omata; K Furukawa
Journal:  Infection       Date:  2014-08-14       Impact factor: 3.553

Review 8.  Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria.

Authors:  Amaylia Oehadian; Prayudi Santoso; Dick Menzies; Rovina Ruslami
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-01-20

9.  Continuous Versus Intermittent Linezolid Infusion for Critically Ill Patients with Hospital-Acquired and Ventilator-Associated Pneumonia: Efficacy and Safety Challenges.

Authors:  Ahmed E Abou Warda; Rania M Sarhan; Hussein Saeed Al-Fishawy; Ayman N Moharram; Heba F Salem
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.